| Name | Title | Contact Details |
|---|---|---|
Simone Steiner |
Chief Technical Operations Officer | Profile |
Denali Therapeutics Inc. (“Denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).
Omnicia is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At IFM Therapeutics, LLC, we work to improve the lives of patients with inflammatory disorders and cancer by developing transformative medicines that precisely target the innate immune system, the body`s first line of immunological response and an essential component of immune function.
For thousands of years, people have discovered medicines from fungi by brewery. This approach has led to transformative medicines that saved millions of lives and have altered the course of medical history. Drug discovery by brewery proved to be difficult and time-consuming, leaving the field in search of a disruptive technological solution. Our genomically-enabled drug discovery engine is precisely that solution, dramatically accelerating the search for nature’s breakthrough drugs. At LifeMine, genomicists, bioinformaticians and microbiologists identify new evolutionary solutions for disease intervention; natural products chemists access the natural molecules that inspire our drug discovery efforts; biologist and chemist drug hunters craft these into disruptively innovative medicines, and translational medical scientists bring the life-saving solutions forward into patients in need.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.